Drug Patents owned by Janssen Biotech
1. Drug name - BALVERSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
May, 2031
(8 years from now) | |
| CN102858765B | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitor |
Apr, 2031
(8 years from now) | |
| CN104725362B | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitor |
Apr, 2031
(8 years from now) | |
| CN104725362A | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitor |
Apr, 2031
(8 years from now) | |
| CN102858765A | JANSSEN BIOTECH | Pyrazolyl Quinazoline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| IN201202591P3 | JANSSEN BIOTECH | Pyrazolyl Quinazoline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| IN325020B | JANSSEN BIOTECH | A Process For The Preparation Of A Compound Of Formula (I) |
Apr, 2031
(8 years from now) | |
| EP3590934A1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP2563775B1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP3178818B1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP3590934B1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP3178818A1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| EP2563775A1 | JANSSEN BIOTECH | Pyrazolyl Quinoxaline Kinase Inhibitors |
Apr, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(8 years from now) | |
| US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(12 years from now) | |
| US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(13 years from now) | |
| US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(15 years from now) | |
Drugs and Companies using ERDAFITINIB ingredient
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | TABLET;ORAL | Prescription |
| 4MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
2. Drug name - ERLEADA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9388159 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(4 years from now) | |
| US8445507 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Sep, 2030
(7 years from now) | |
| US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(10 years from now) | |
| CN104619692A | JANSSEN BIOTECH | Crystalline Form Of Androgen Receptor Regulator |
Oct, 2019
(2 years ago) | |
| CN105693692A | JANSSEN BIOTECH | Crystalline Form Of Androgen Receptor Modulator |
Sep, 2021
(1 year, 6 days ago) | |
| CN101454002B | JANSSEN BIOTECH | For The Treatment Of Prostate Cancer And The Androgen Receptor-Related Disease Of Androgen Receptor Modulators |
Mar, 2027
(4 years from now) | |
| CN101454002A | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| IN200809025P1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Disease |
Mar, 2027
(4 years from now) | |
| IN283620B | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptorassociated Disease |
Mar, 2027
(4 years from now) | |
| EP2656841B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2004181A2 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656841A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3100727A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656842B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2004181B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3412290A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656842A3 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2656842A2 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3100727B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP3412290B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2004181A4 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2368550A1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2368550B1 | JANSSEN BIOTECH | Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases |
Mar, 2027
(4 years from now) | |
| EP2858985A4 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3348553B1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP2858985B1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3348553A1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP2858985A1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3533792B1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| EP3533792A1 | JANSSEN BIOTECH | Crystalline Forms Of An Androgen Receptor Modulator |
Jun, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802689 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Mar, 2027
(4 years from now) | |
| US9987261 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(4 years from now) | |
| US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(10 years from now) | |
| US10702508 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Apr, 2038
(15 years from now) | |
Drugs and Companies using APALUTAMIDE ingredient
Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 60MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.